## Edgar Filing: Valentine Karen - Form 4

Valentine Ka Form 4 October 28, 2											
FORM	14							-	OMB APPROVAL		
	UNITED	Washington, D.C. 20549						OMB Number:	3235-0287		
Check th if no long	ar.	X							January 31, 2005		
subject to Section 1	5 SIAIEM	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES									
								burden hou response n	•		
(Print or Type I	Responses)										
V-1- V- V-			2. Issuer Name <b>and</b> Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer				
		ANTIO	NTIGENICS INC /DE/ [AGEN]				(Check all applicable)				
(Last)	(First) (N		3. Date of Earliest Transaction								
C/O ANTIGENICS INC., 3 FORBES RD			(Month/Day/Year) 10/26/2010				Director 10% Owner X Officer (give title Other (specify below) below) VP and General Counsel				
	(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line)						
LEXINGTO	DN, MA 02421						_X_ Form filed by 0 Form filed by M Person				
(City)	(State)	(Zip) Tal	ole I - Non-D	Derivative	Secur	ities Ac	quired, Disposed o	f, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	(Month/Day/Year) Execution any					d of	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				
Common Stock	10/26/2010		A <u>(1)</u>	2,500	А	\$ 0.98	58,991	D			
Common Stock	10/27/2010		S <u>(2)</u>	2,500	D	\$ 0.98	56,491	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: Valentine Karen - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	7. Titl Amou Under Securi (Instr.	int of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Own Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## **Reporting Owners**

Reporting Owner Name / Address	ss Relationships							
I B	Director	10% Owner	Officer	Other				
Valentine Karen C/O ANTIGENICS INC. 3 FORBES RD LEXINGTON, MA 02421			VP and General Counsel					
Signatures								
Christine M. Klaskin, by Powe Attorney	r of	10/	/28/2010					
<b>**</b> Signature of Reporting Person			Date					

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents settlement of restricted stock awarded on January 26, 2010.

(2) Represents the sale of shares obtained from the vesting of the restricted stock awarded on January 26, 2010. This sale was made through a 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.